A Phase I/IIa, Open-label, Dose Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
Latest Information Update: 29 Feb 2024
At a glance
- Drugs SGN-1 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Penile cancer; Pseudomyxoma peritonei; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Guangzhou Sinogen Pharmaceutical
- 22 Feb 2024 Planned number of patients changed from 50 to 70.
- 22 Feb 2024 Planned End Date changed from 31 Oct 2025 to 30 Jun 2028.
- 22 Feb 2024 Planned primary completion date changed from 30 Apr 2025 to 31 Dec 2027.